Abstract
Fibroblast growth factor (FGF) 23 and αKlotho are circulating mineral regulatory substances that also have a very diverse range of actions. Acute kidney injury (AKI) is a state of high FGF23 and low αKlotho. Clinical association data for FGF23 are strong, but the basic pathobiology of FGF23 in AKI is rather sparse. Conversely, preclinical data supporting a pathogenic role of αKlotho in AKI are strong, but the human data are still being generated. This pair of substances can potentially serve as diagnostic and prognostic biomarkers. FGF23 blockade and αKlotho restoration can have prophylactic and therapeutic utility in AKI. The literature to date is briefly reviewed in this article.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 665-672 |
| Number of pages | 8 |
| Journal | Nephron |
| Volume | 144 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2020 |
Keywords
- Acute kidney injury
- Biomarker
- Chronic kidney disease
- FGF23
- Klotho
- Treatment
ASJC Scopus subject areas
- Nephrology
- Urology
- Physiology (medical)
- Physiology